A personalized mRNA-based cancer vaccine has demonstrated promising initial results in its first clinical application. The first patient undergoing treatment for skin cancer is reported to be in good overall condition following the initial administration. Immunological assessments confirm that the treatment has triggered positive biological responses, stimulating the production of targeted immune-active compounds.

The therapeutic regimen involves a total of three vaccinations tailored specifically to the genetic profile of each patient's individual tumor. Developed as a major advance in precision oncology, the personalized vaccine is provided free of charge under the Mandatory Health Insurance (OMS) program, making cutting-edge immunotherapy accessible to eligible patients.